Preskoči na sadržaj
Korištenjem servisa na Twitteru pristajete na korištenje kolačića. Twitter i partneri rade globalno te koriste kolačiće za analize, personalizaciju i oglase.

Za najbolje sučelje na Twitteru koristite Microsoft Edge ili instalirajte aplikaciju Twitter iz trgovine Microsoft Store.

  • Naslovnica Naslovnica Naslovnica, trenutna stranica.
  • O Twitteru

Spremljena pretraživanja

  • obriši
  • U ovom razgovoru
    Ovjeren akauntZaštićeni tweetovi @
Predloženi korisnici
  • Ovjeren akauntZaštićeni tweetovi @
  • Ovjeren akauntZaštićeni tweetovi @
  • Jezik: Hrvatski
    • Bahasa Indonesia
    • Bahasa Melayu
    • Català
    • Čeština
    • Dansk
    • Deutsch
    • English
    • English UK
    • Español
    • Filipino
    • Français
    • Italiano
    • Magyar
    • Nederlands
    • Norsk
    • Polski
    • Português
    • Română
    • Slovenčina
    • Suomi
    • Svenska
    • Tiếng Việt
    • Türkçe
    • Български език
    • Русский
    • Српски
    • Українська мова
    • Ελληνικά
    • עִבְרִית
    • العربية
    • فارسی
    • मराठी
    • हिन्दी
    • বাংলা
    • ગુજરાતી
    • தமிழ்
    • ಕನ್ನಡ
    • ภาษาไทย
    • 한국어
    • 日本語
    • 简体中文
    • 繁體中文
  • Imate račun? Prijava
    Imate račun?
    · Zaboravili ste lozinku?

    Novi ste na Twitteru?
    Registrirajte se
Profil korisnika/ce murphey_richard
Richard Murphey
Richard Murphey
Richard Murphey
@murphey_richard

Tweets

Richard Murphey

@murphey_richard

biotech

baybridgebio.com
Vrijeme pridruživanja: travanj 2017.

Tweets

  • © 2020 Twitter
  • O Twitteru
  • Centar za pomoć
  • Uvjeti
  • Pravila o privatnosti
  • Imprint
  • Kolačići
  • Informacije o oglasima
Odbaci
Prethodni
Sljedeće

Idite na profil osobe

Spremljena pretraživanja

  • obriši
  • U ovom razgovoru
    Ovjeren akauntZaštićeni tweetovi @
Predloženi korisnici
  • Ovjeren akauntZaštićeni tweetovi @
  • Ovjeren akauntZaštićeni tweetovi @

Odjava

Blokiraj

  • Objavi Tweet s lokacijom

    U tweetove putem weba ili aplikacija drugih proizvođača možete dodati podatke o lokaciji, kao što su grad ili točna lokacija. Povijest lokacija tweetova uvijek možete izbrisati. Saznajte više

    Vaši popisi

    Izradi novi popis


    Manje od 100 znakova, neobavezno

    Privatnost

    Kopiraj vezu u tweet

    Ugradi ovaj Tweet

    Embed this Video

    Dodajte ovaj Tweet na svoje web-mjesto kopiranjem koda u nastavku. Saznajte više

    Dodajte ovaj videozapis na svoje web-mjesto kopiranjem koda u nastavku. Saznajte više

    Hm, došlo je do problema prilikom povezivanja s poslužiteljem.

    Integracijom Twitterova sadržaja u svoje web-mjesto ili aplikaciju prihvaćate Twitterov Ugovor za programere i Pravila za programere.

    Pregled

    Razlog prikaza oglasa

    Prijavi se na Twitter

    · Zaboravili ste lozinku?
    Nemate račun? Registrirajte se »

    Prijavite se na Twitter

    Niste na Twitteru? Registrirajte se, uključite se u stvari koje vas zanimaju, i dobivajte promjene čim se dogode.

    Registrirajte se
    Imate račun? Prijava »

    Dvosmjerni (slanje i primanje) kratki kodovi:

    Država Kod Samo za korisnike
    Sjedinjene Američke Države 40404 (bilo koje)
    Kanada 21212 (bilo koje)
    Ujedinjeno Kraljevstvo 86444 Vodafone, Orange, 3, O2
    Brazil 40404 Nextel, TIM
    Haiti 40404 Digicel, Voila
    Irska 51210 Vodafone, O2
    Indija 53000 Bharti Airtel, Videocon, Reliance
    Indonezija 89887 AXIS, 3, Telkomsel, Indosat, XL Axiata
    Italija 4880804 Wind
    3424486444 Vodafone
    » Pogledajte SMS kratke šifre za druge zemlje

    Potvrda

     

    Dobro došli kući!

    Vremenska crta mjesto je na kojem ćete provesti najviše vremena i bez odgode dobivati novosti o svemu što vam je važno.

    Tweetovi vam ne valjaju?

    Prijeđite pokazivačem preko slike profila pa kliknite gumb Pratim da biste prestali pratiti neki račun.

    Kažite mnogo uz malo riječi

    Kada vidite Tweet koji volite, dodirnite srce – to osobi koja ga je napisala daje do znanja da vam se sviđa.

    Proširite glas

    Najbolji je način da podijelite nečiji Tweet s osobama koje vas prate prosljeđivanje. Dodirnite ikonu da biste smjesta poslali.

    Pridruži se razgovoru

    Pomoću odgovora dodajte sve što mislite o nekom tweetu. Pronađite temu koja vam je važna i uključite se.

    Saznajte najnovije vijesti

    Bez odgode pogledajte o čemu ljudi razgovaraju.

    Pratite više onoga što vam se sviđa

    Pratite više računa da biste dobivali novosti o temama do kojih vam je stalo.

    Saznajte što se događa

    Bez odgode pogledajte najnovije razgovore o bilo kojoj temi.

    Ne propustite nijedan aktualni događaj

    Bez odgode pratite kako se razvijaju događaji koje pratite.

    Richard Murphey‏ @murphey_richard 20. stu 2019.
    • Prijavi Tweet

    Anyone interested in biotech entrepreneurship should check out the interviews with Genentech's founders conducted by Sally Smith Hughes for her book Genentech: The Beginnings of Biotech: https://bancroft.berkeley.edu/ROHO/projects/biosci/oh_list.html …

    12:49 - 20. stu 2019.
    • 1 proslijeđeni Tweet
    • 3 oznake „sviđa mi se”
    • Vincent Weisser Ben Kamens Nisarg Patel
    1 reply 1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
      1. Novi razgovor
      2. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech was founded by an unemployed 29 year old in 1976, less than a week after Apple was founded. It went public in 1980, a few months before Apple.pic.twitter.com/sqVqfsgzVL

        1 reply 0 proslijeđenih tweetova 1 korisnik označava da mu se sviđa
        Prikaži ovu nit
      3. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Bob Swanson, Genentech's founding CEO, did for biotech what Steve Jobs and Bill Gates did for the computer industry.pic.twitter.com/c4ItFI2S6K

        1 reply 0 proslijeđenih tweetova 1 korisnik označava da mu se sviđa
        Prikaži ovu nit
      4. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        To get a sense of how Bob's mind worked, I've highlighted some quotes below. These mostly come from this fascinating interview with Bob, conducted by Sally Smith Hughes: https://oac.cdlib.org/view?docId=kt9c6006s1&query=&brand=oac4 …

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      5. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Early Genentech focused on systematically eliminating risk. Eliminating risk creates value. As Josh Wolfe says, “Entrepreneurs aren’t risk takers. They’re risk killers”pic.twitter.com/qvL7x7juHF

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      6. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Bob’s strategy for building a profitable pharma company: raise money, eliminate risk and create value, raise more money, create more value.pic.twitter.com/yvUYfLSHHn

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      7. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Fundamentally, Bob focused on creating value for patients. In the words of Paul Graham, “make something people want”.pic.twitter.com/xl2BIHvWRp

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      8. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech took big risks, but its rigorous, science-first culture was essential to figuring out which risks were worth taking.pic.twitter.com/AE3cPoM0Ja

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      9. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Bob and his cofounder, Herb Boyer, knew that the best way to create value was through great science. They focused on finding and empowering the best young scientists in the world.pic.twitter.com/Mo0AS6tWAn

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      10. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech’s ambition was key to recruiting the best people. As Sam Altman says, “It’s easier to do a hard startup than an easy startup. People want to be part of something exciting and feel that their work matters.”pic.twitter.com/87iC9TDagw

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      11. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech was building perhaps the most powerful platform in biotech history. But they focused on products, not the platform -- if they made great products for patients, the platform would follow.pic.twitter.com/RZpmtL6TvF

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      12. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        But before jumping into expensive product development, they focused on addressing a key technical risk: could bacteria express a human gene?pic.twitter.com/ZpW99WZWiq

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      13. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        They focused on "killer experiments" to address risks, robustly, quickly and cheaply.pic.twitter.com/rdBM8ZYNiD

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      14. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech's first product was insulin: there was a validated unmet need for safer, cheaper insulin; the product was technically feasible (small peptide vs. more complex protein); the economics were good; it was patentable.pic.twitter.com/QMce4CPoAV

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      15. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Another benefit of insulin as an initial product was that insulin was known to improve clinical outcomes for people with diabetes. Low clinical risk + best-in-class product = great initial indication for new techpic.twitter.com/KQ9aCcopIG

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      16. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        The short path to human proof of concept for insulin was also attractive: short studies, objective endpoints, and an approvable biomarker endpoint with high correlation to clinical outcomes.pic.twitter.com/5Tl0A2W8YV

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      17. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        The only downside of insulin as an initial product was that Genentech couldn't market it themselves. They had to partner with a big company for commercialization. For startups, low-prevalence indications with high unmet need > highly prevalent indicationspic.twitter.com/0U07yBSpeC

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      18. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech's goal was always to develop and sell their own products, rather than just licensing projects to pharma. The value of a drug increases exponentially as it advances through the development process.pic.twitter.com/XAemzvA2h7

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      19. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Financing risk is always huge for pre-revenue biopharma companies, especially for those that want to sell their own products. Bob was acutely aware of this and focused on profitability. He partnered non-core assets to fund work on core products.pic.twitter.com/xRSnK8Ix2w

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      20. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Today the idea of a profitable biopharma startup almost seems ridiculous. It is incredible that Bob had profitability as a goal -- and achieved it. Perhaps that's why Genentech was able to survive as an independent company for so long.

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      21. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        Genentech's focus on capital efficiency was another key tactic that reduced financing risk and let them stay independent.pic.twitter.com/WO9NKuaM0Y

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      22. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        But perhaps the most important thing Bob brought to Genentech was his determination, optimism and ability to get things done. Those traits more than made up for his lack of experience.pic.twitter.com/1Ic3HOC2gt

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      23. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        All of the quotes above are from Sally Smith Hughes' interviews from Berkeley's Bancroft Library Oral History Center. https://bancroft.berkeley.edu/ROHO/projects/biosci/oh_list.html …

        1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa
        Prikaži ovu nit
      24. Richard Murphey‏ @murphey_richard 20. stu 2019.
        • Prijavi Tweet

        If you want to learn more, read Sally Smith Hughes' book Genentech: The Beginnings of Biotech. It's a quick and engaging read. You can also check out an article I wrote with a bit more context on the above quotes:https://www.baybridgebio.com/blog/lessons-from-genentech.html …

        0 replies 0 proslijeđenih tweetova 1 korisnik označava da mu se sviđa
        Prikaži ovu nit
      25. Kraj razgovora

    Čini se da učitavanje traje već neko vrijeme.

    Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

      Sponzorirani tweet

      false

      • © 2020 Twitter
      • O Twitteru
      • Centar za pomoć
      • Uvjeti
      • Pravila o privatnosti
      • Imprint
      • Kolačići
      • Informacije o oglasima